UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) November 15, 2006
Calypte Biomedical Corporation
(Exact name of Company as specified in its charter)
| | | |
Delaware | 000-20985 | 06-1226727 |
(State or Other Jurisdiction) | (Commission File Number) | (I.R.S. Employer Identification) |
of Incorporation) | | |
5 Centerpointe Drive, Suite 400, Lake Oswego, OR 97035
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (971) 204-0282
N/A
(Former name or former address, if changed since last report)
|_| Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 40.13e-4(c))
Item 7.01 - Regulation FD Disclosure.
On November 15, 2006, Calypte Biomedical Corporation (the “Company”) held a webcast conference call with analysts and investors, during which Roger I. Gale, the Company’s Chairman and Chief Executive Officer, and Theodore R. Gwin, the Company’s Chief Financial Officer, discussed the Company’s financial results for the quarter ended September 30, 2006 and provided an update on the Company’s operations. A copy of the prepared remarks of Messrs. Gale and Gwin is attached as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.
Item 9.01 - Financial Statements and Exhibits.
(d) Exhibits
| | | |
Exhibit Number | | Description |
| 99.1 | | Prepared Remarks of Roger I. Gale and Theodore R. Gwin for Calypte Biomedical Corporation Third Quarter 2006 Analyst/Investor Conference Call held on November 15, 2006. |
| | | |
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 17, 2006
Calypte Biomedical Corporation
By: /s/ Theodore R. Gwin
Theodore R. Gwin
Chief Financial Officer
